WO2010129467A8 - Compounds and methods for inhibition of renin, and indications therefor - Google Patents
Compounds and methods for inhibition of renin, and indications therefor Download PDFInfo
- Publication number
- WO2010129467A8 WO2010129467A8 PCT/US2010/033385 US2010033385W WO2010129467A8 WO 2010129467 A8 WO2010129467 A8 WO 2010129467A8 US 2010033385 W US2010033385 W US 2010033385W WO 2010129467 A8 WO2010129467 A8 WO 2010129467A8
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compounds
- renin
- methods
- inhibition
- indications therefor
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 102100028255 Renin Human genes 0.000 title abstract 2
- 108090000783 Renin Proteins 0.000 title abstract 2
- 230000005764 inhibitory process Effects 0.000 title 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000036454 renin-angiotensin system Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/04—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms
- C07D215/06—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms having only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to the ring nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SG2011081015A SG175877A1 (en) | 2009-05-04 | 2010-05-03 | Compounds and methods for inhibition of renin, and indications therefor |
MX2011011735A MX2011011735A (en) | 2009-05-04 | 2010-05-03 | Compounds and methods for inhibition of renin, and indications therefor. |
CA2761009A CA2761009A1 (en) | 2009-05-04 | 2010-05-03 | Compounds and methods for inhibition of renin, and indications therefor |
IL216107A IL216107A0 (en) | 2009-05-04 | 2011-11-03 | Compounds and methods for inhibition of renin, and indications therefor |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17541709P | 2009-05-04 | 2009-05-04 | |
US61/175,417 | 2009-05-04 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2010129467A1 WO2010129467A1 (en) | 2010-11-11 |
WO2010129467A8 true WO2010129467A8 (en) | 2010-12-16 |
Family
ID=42237224
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2010/033385 WO2010129467A1 (en) | 2009-05-04 | 2010-05-03 | Compounds and methods for inhibition of renin, and indications therefor |
Country Status (5)
Country | Link |
---|---|
CA (1) | CA2761009A1 (en) |
IL (1) | IL216107A0 (en) |
MX (1) | MX2011011735A (en) |
SG (1) | SG175877A1 (en) |
WO (1) | WO2010129467A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9469640B2 (en) | 2007-07-17 | 2016-10-18 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
US9487515B2 (en) | 2006-11-22 | 2016-11-08 | Plexxikon Inc. | Compounds modulating c-fms and/or c-kit activity and uses therefor |
Families Citing this family (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8158636B2 (en) | 2008-05-19 | 2012-04-17 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
EP2296653B1 (en) | 2008-06-03 | 2016-01-27 | Intermune, Inc. | Compounds and methods for treating inflammatory and fibrotic disorders |
MX2012005827A (en) | 2009-11-18 | 2012-06-19 | Plexxikon Inc | Compounds and methods for kinase modulation, and indications therefor. |
MX2012007429A (en) | 2009-12-23 | 2012-07-23 | Plexxikon Inc | Compounds and methods for kinase modulation, and indications therefor. |
US8598156B2 (en) | 2010-03-25 | 2013-12-03 | Glaxosmithkline Llc | Chemical compounds |
TWI619713B (en) | 2010-04-21 | 2018-04-01 | 普雷辛肯公司 | Compounds and methods for kinase modulation, and indications therefor |
MY162950A (en) | 2011-02-07 | 2017-07-31 | Plexxikon Inc | Compounds and methods for kinase modulation, and indications therefor |
GB201106817D0 (en) | 2011-04-21 | 2011-06-01 | Astex Therapeutics Ltd | New compound |
BR112013029163A2 (en) | 2011-05-17 | 2017-01-31 | Plexxikon Inc | kinase modulation and indications thereof |
CN102993094B (en) * | 2011-09-08 | 2014-07-23 | 中国石油大学(北京) | Synthesizing method of tetrahydroquinoline derivative |
US9358235B2 (en) | 2012-03-19 | 2016-06-07 | Plexxikon Inc. | Kinase modulation, and indications therefor |
UY34893A (en) | 2012-07-10 | 2014-02-28 | Takeda Pharmaceutical | DERIVATIVES OF AZAINDOL |
WO2014039714A2 (en) | 2012-09-06 | 2014-03-13 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
AR092742A1 (en) | 2012-10-02 | 2015-04-29 | Intermune Inc | ANTIFIBROTIC PYRIDINONES |
US9980973B2 (en) | 2012-10-19 | 2018-05-29 | Astex Therapeutics Limited | Bicyclic heterocycle compounds and their uses in therapy |
GB201218862D0 (en) | 2012-10-19 | 2012-12-05 | Astex Therapeutics Ltd | Bicyclic heterocycle compounds and their uses in therapy |
GB201218864D0 (en) | 2012-10-19 | 2012-12-05 | Astex Therapeutics Ltd | Bicyclic heterocycle compounds and their uses in therapy |
GB201218850D0 (en) | 2012-10-19 | 2012-12-05 | Astex Therapeutics Ltd | Bicyclic heterocycle compounds and their uses in therapy |
NZ711896A (en) | 2012-12-21 | 2018-04-27 | Plexxikon Inc | Compounds and methods for kinase modulation, and indications therefor |
US20140303121A1 (en) | 2013-03-15 | 2014-10-09 | Plexxikon Inc. | Heterocyclic compounds and uses thereof |
DK2970265T3 (en) | 2013-03-15 | 2018-10-01 | Plexxikon Inc | HETEROCYCLIC COMPOUNDS AND APPLICATIONS THEREOF |
US9181272B2 (en) | 2013-04-30 | 2015-11-10 | Boehringer Ingelheim International Gmbh | Aldosterone synthase inhibitors |
RU2015149937A (en) | 2013-05-30 | 2017-07-06 | Плексксикон Инк. | COMPOUNDS FOR KINASE MODULATION AND INDICATIONS FOR THEIR APPLICATION |
CA2927252C (en) | 2013-10-25 | 2021-09-28 | Novartis Ag | Ring-fused bicyclic pyridyl derivatives as fgfr4 inhibitors |
US9783538B2 (en) | 2013-12-20 | 2017-10-10 | Astex Therapeutics Limited | Bicyclic heterocycle compounds and their uses in therapy |
WO2015106012A1 (en) | 2014-01-09 | 2015-07-16 | Takeda Pharmaceutical Company Limited | Azaindole derivatives |
US9771369B2 (en) | 2014-03-04 | 2017-09-26 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
RU2692485C2 (en) | 2014-04-02 | 2019-06-25 | Интермьюн, Инк. | Antifibrous pyridinones |
US9856259B2 (en) | 2014-09-15 | 2018-01-02 | Plexxikon Inc. | Heterocyclic compounds and uses thereof |
EP3200786B1 (en) | 2014-10-03 | 2019-08-28 | Novartis AG | Use of ring-fused bicyclic pyridyl derivatives as fgfr4 inhibitors |
US9802917B2 (en) | 2015-03-25 | 2017-10-31 | Novartis Ag | Particles of N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide |
US10160755B2 (en) | 2015-04-08 | 2018-12-25 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
WO2017019804A2 (en) | 2015-07-28 | 2017-02-02 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
PE20181093A1 (en) | 2015-09-21 | 2018-07-09 | Plexxikon Inc | HETEROCYCLIC COMPOUNDS AND USES OF THEM |
CA3007462C (en) | 2015-12-07 | 2023-10-24 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
ES2904615T3 (en) | 2016-03-16 | 2022-04-05 | Plexxikon Inc | Compounds and methods for the modulation of kinases and indications therefor |
TW201815766A (en) | 2016-09-22 | 2018-05-01 | 美商普雷辛肯公司 | Compounds and methods for IDO and TDO modulation, and indications therefor |
US10703757B2 (en) | 2016-12-23 | 2020-07-07 | Plexxikon Inc. | Compounds and methods for CDK8 modulation and indications therefor |
US10577366B2 (en) | 2017-03-20 | 2020-03-03 | Plexxikon Inc. | Crystalline forms of a compound that inhibits bromodomain |
US10428067B2 (en) | 2017-06-07 | 2019-10-01 | Plexxikon Inc. | Compounds and methods for kinase modulation |
TWI805599B (en) | 2017-07-25 | 2023-06-21 | 美商第一三共公司 | Formulations of a compound modulating kinases |
CA3079029A1 (en) | 2017-10-13 | 2019-04-18 | Plexxikon Inc. | Solid forms of a compound for modulating kinases |
CN112165958A (en) | 2017-10-27 | 2021-01-01 | 普莱希科公司 | Formulations of compounds for modulating kinases |
JP2021518367A (en) | 2018-03-20 | 2021-08-02 | プレキシコン インコーポレーテッドPlexxikon Inc. | Compounds and methods for IDO and TDO regulation, and signs for them |
CN108752272B (en) * | 2018-06-19 | 2021-02-19 | 西安交通大学 | 8-aminoquinoline amide derivative, preparation method, application and fluorescence analysis method thereof |
US11958818B2 (en) | 2019-05-01 | 2024-04-16 | Boehringer Ingelheim International Gmbh | (R)-(2-methyloxiran-2-yl)methyl 4-bromobenzenesulfonate |
CN111053761B (en) * | 2020-01-16 | 2022-05-03 | 杭州旦承医药科技有限公司 | Bisphosphonic acid medicine for inhalation, preparation method thereof and application thereof in chronic obstructive pulmonary disease |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6197959B1 (en) * | 1999-04-27 | 2001-03-06 | Hoffmann-La Roche Inc. | Piperidine derivatives |
JP2010208947A (en) * | 2007-06-29 | 2010-09-24 | Dainippon Sumitomo Pharma Co Ltd | Quinolone derivative |
-
2010
- 2010-05-03 SG SG2011081015A patent/SG175877A1/en unknown
- 2010-05-03 MX MX2011011735A patent/MX2011011735A/en not_active Application Discontinuation
- 2010-05-03 WO PCT/US2010/033385 patent/WO2010129467A1/en active Application Filing
- 2010-05-03 CA CA2761009A patent/CA2761009A1/en active Pending
-
2011
- 2011-11-03 IL IL216107A patent/IL216107A0/en unknown
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9487515B2 (en) | 2006-11-22 | 2016-11-08 | Plexxikon Inc. | Compounds modulating c-fms and/or c-kit activity and uses therefor |
US9469640B2 (en) | 2007-07-17 | 2016-10-18 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
Also Published As
Publication number | Publication date |
---|---|
SG175877A1 (en) | 2011-12-29 |
WO2010129467A1 (en) | 2010-11-11 |
IL216107A0 (en) | 2012-01-31 |
CA2761009A1 (en) | 2010-11-11 |
MX2011011735A (en) | 2011-11-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2010129467A8 (en) | Compounds and methods for inhibition of renin, and indications therefor | |
WO2012037155A3 (en) | Tyrosine kinase inhibitors | |
WO2011014795A3 (en) | Compounds and compositions as syk kinase inhibitors | |
SG190819A1 (en) | Nampt and rock inhibitors | |
WO2013134336A3 (en) | Inhibition of adaptor associated kinase 1 for the treatment of pain | |
WO2008112199A8 (en) | Method for inhibiting topoisomerase ii | |
MY162936A (en) | Macrocycles as factor xia inhibitors | |
EP2595482A4 (en) | Aldosterone synthase inhibitors | |
WO2011126903A3 (en) | Multisubstituted aromatic compounds as inhibitors of thrombin | |
WO2007092213A3 (en) | Inhibitors of e1 activating enzyme | |
WO2013003298A3 (en) | Inhibitors of pde10 | |
UA104885C2 (en) | Isothiazolyloxyphenyl amidines and use thereof as fungicides | |
WO2011138328A3 (en) | Use of inhibitory molecules for the treatment of pulmonary hypertension | |
EA201200917A1 (en) | PROCARAXES OF PLASMA KALLIKREIN INHIBITORS | |
AU2012249851A8 (en) | MicroRNA compounds and methods for modulating miR-21 activity | |
MX2011011854A (en) | Dihydropyrimidinones for use as bace2 inhibitors. | |
WO2008118332A3 (en) | Hydrazido-peptides as inhibitors of hcv ns3-protease | |
MY153766A (en) | Derivatised proline containing peptide organic compounds as protease inhibitors | |
UA111861C2 (en) | Aromatic heterocyclic dihydroxy compound | |
WO2011119777A3 (en) | Compositions and methods for treatment of neurodegenerative disease | |
AU2011326186A8 (en) | Selective glycosidase inhibitors and uses thereof | |
MX2012004780A (en) | Akt inhibitors. | |
WO2012065102A8 (en) | S-t-butyl protected cysteine di-peptide analogs and related compounds | |
MX2011011272A (en) | Processes and intermediates. | |
UA110807C2 (en) | CRYSTALLINE FORMS OF HYDROCHLORIDE SALT OF (4A-R,9A-S)-1-(1H-BENZOIMIDAZOLE- 5-CARBONYL)-2,3,4,4A,9,9A -HEXAHYDRO -1H-INDENO [2,1-b]PYRIDINE-6 -CARBONITRILE AND THEIR USE AS HSD 1 INHIBITORS |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10717397 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2012509872 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: CR2011-000570 Country of ref document: CR |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2011002764 Country of ref document: CL Ref document number: 2761009 Country of ref document: CA Ref document number: 11150238 Country of ref document: CO Ref document number: 001901-2011 Country of ref document: PE Ref document number: MX/A/2011/011735 Country of ref document: MX |
|
NENP | Non-entry into the national phase |
Ref country code: JP |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 10717397 Country of ref document: EP Kind code of ref document: A1 |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: PI1014458 Country of ref document: BR |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01E Ref document number: PI1014458 Country of ref document: BR Free format text: APRESENTAR, EM ATE 60 (SESSENTA) DIAS, EM LINGUA PORTUGUESA, AS FOLHAS DE RELATORIO DESCRITIVO E DESENHOS APRESENTADAS EM LINGUA ESTRANGEIRA NA PETICAO NO 020110112782 DE 03/11/2011, ADAPTADO A NORMA VIGENTE. |
|
ENPW | Started to enter national phase and was withdrawn or failed for other reasons |
Ref document number: PI1014458 Country of ref document: BR |